PRESCIENT THERAPEUTICS LIMITED (PTX)

---

AI Coverage Rating: Low

ASX AI Signals has generated 0 signals for PTX during the last 90 days, indicating low trading activity

PTX Share Price
Current Price	$0.068
52 Week High	$0.105
52 Week Low:	$0.040
Trading at (% of 52 Week High)	64.76%

Business Overview

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing novel targeted cancer therapies. The company is advancing treatments designed to address difficult-to-treat cancers, including brain tumors and blood cancers. Their pipeline includes several drug candidates in various stages of clinical development.

ASX Sector Overview

Sector:   Pharmaceuticals, Biotechnology & Life Sciences

The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.

Latest AI Recommendation

The SELL recommendation for PTX is supported by weak price performance and potential sector volatility. However, limited liquidity and market capitalization introduce some uncertainty, moderating the confidence level.

Latest  PRESCIENT THERAPEUTICS LIMITED(PTX)   News

15 Dec 2025, 01:29 PM

Just The Facts: Lindian Resources, Prescient Therapeutics, Tamboran Resources

In today's Just The Facts.. Lindian Resources has hosted senior US Government officials at its Kangankunde rare earths project in Malawi, highlighting development progress and its potential role in supplying high-grade rare earths to global markets, amid growing US focus on securing critical mineral